An allogeneic irradiated @entity1358 cell line, engineered to produce @entity1199 ( @entity1199 ), admixed with autologous metastatic @entity406 -treated @entity5 cells, was used to vaccinate ten MRCC @entity1 in progression of disease in spite of @entity1199 immunotherapy. The cells were administered subcutaneously and/or intra-tumourally. Sixty-four MRCC @entity1 in progressive disease, not treated by vaccination but receiving similar @entity1199 immunotherapy, were considered as the control group. @entity1 received 4-16 injections (mean 9 +/- 4), containing an average of 10.6 x 10(7) +/- 7.7 x 10(7) @entity1199 -transfected cells (a minimum of 4 x 10(7), and a maximum of 31 x 10(7)). Four @entity1 also received intra- @entity5 injections. Vaccination was administered during 30-418 days, and the follow-up continued for 649 +/- 353 days (190-1342). Throughout this period, the @entity1 continued receiving the previously set immunotherapy treatment. No adverse side effects related to the treatment were observed. One complete and one partial @entity5 response were observed, as well as two stable and one no-relapse disease. All but one @entity1 died. Responding @entity1 resumed progression in 4-11 months and died 18 and 36 months after beginning the vaccine therapy. In spite of the small number of treated @entity1 , Wilcoxon's test showed a significant (P < 0.05) improvement of the survival in the vaccinated group compared to that of the control. The described vaccination protocol seems safe, devoid of adverse side effects and promising. It warrants further investigation.

Allogeneic gene-modified XXXX cells in metastatic kidney cancer. Preliminary report.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['RCC'] @entity1199 :: ('3558', 'Gene') :: ['ACHN-IL-2', 'IL-2']
@entity5 :: (MESH:D009369,Disease) :: ['tumour']
